Genasense Genta Inc

Current Opinion in Investigational Drugs

Volumn 2, Issue 4, 2001, Pages 574-580

  Banerjee, D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOCETAXEL; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; OBLIMERSEN; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLON CANCER; COLORECTAL TUMOR; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; DRUG SYNTHESIS; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TOLERABILITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE THERAPY; HUMAN; LEUKEMIA; LUNG SMALL CELL CANCER; LYMPHOMA; MELANOMA; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; NONHUMAN; PROSTATE CANCER; PROTO ONCOGENE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; THIONUCLEOTIDES;

EID: 0035043265     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Preclinical pharmacokinetics of G3139, a phosphorothioate antisense to bcl-2 in mice
2. Genta announces collaboration with National Cancer Institute for its anticode drug G3139
3. Drug development pipeline
4. The preclinical and clinical experience of antisense oligonucleotides that target Bcl2 expression
5. Antisense oligonucleotides containing chirally pure methylphosphonates are potent and specific cleavers of RNA or inhibitors of pre-mRNA processing and are active in vitro
6. A preclinical pharmacokinetic study of G3139, a phosphorothioate antisense oligodeoxynucleotide to BCL-2, in Balb/c mice
7. Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: Comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides
8. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies
9. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence
10. Genta announces initiation of phase I/IIa prostate cancer trial at Memorial Sloan Kettering Cancer Center
11. Article in leading scientific journal spotlights use of Genta's bcl-2 antisense compound in increasing response to a chemotherapeutic drug
12. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2; after intravenous administration or continuous subcutaneous infusion to mice
13. Genta announces issue of patent for lead antisense compound that targets the Bcl-2 gene, implicated in prostate and other cancers
14. Genta announces the issuance of two patents directed to high potency antisense compounds that target the production of disease causing pre-RNA
15. Genta to commence phase I/IIa malignant melanoma trial of bcl-2 antisense compound in combination with a chemotherapeutic drug; Preclinical studies showed significant tumor reduction in mouse transplant model of human melanoma
16. Genta signs letter of intent with National Cancer Institute for collaborative research & development agreement/Collaboration will study G3139 in various cancers
17. Genta to commence second phase I/IIa prostate cancer trial of Bcl-2 antisense compound
18. BCL-2 antisense therapy: In vitro, in vivo and human trial experiences in haematological malignancies
19. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
20. Antisense 98: Targeting The Molecular Basis Of Disease (Part III), Organized By Nature Biotechnology, London, UK
21. Genta to commence phase I/IIa prostate cancer trial of bcl-2 antisense compound administered with mitoxantrone
22. Report at American Association for Cancer Research meeting presents scientific basis for clinical trial now underway at British Columbia Cancer Agency / Bcl-2 antisense shows potent anti-tumor effects in preclinical models of prostate cancer
23. Genta to commence phase I/IIa lymphoma trial of Bcl-2 antisense compound administered with cyclophosphamide
24. Royal Marsden Hospital to commence phase II trial of Genta's Bcl-2 antisense compound G3139 in non-Hodgkin's lymphoma
25. Antisense oligonucleotide therapeutics
26. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance
27. Reversal of chemoresistance of lymphoma cells by antisense mediated reduction of bcl-2 gene expression
28. Genta enters cooperative research and development agreement with National Cancer Institute
29. Genta to commence phase I/IIa trial of Bcl-2 antisense compound administered with Taxotere (docetaxel) at Lombardi Cancer Center
30. Investigators report activity in clinical studies of Genta's antisense product in drug-resistant cancers
31. Genta develops oncogene inhibitor as antisense drug
32. A phase II study with dacarbazine and BCL-2 antisense oligonucleotide G-3139 (Genta) as a chemosensitizer in patients with advanced malignant melanoma
33. Genta Inc announces second quarter 1999 results
34. NCI commences trial of Genta's bcl-2 antisense compound combined with irinotecan for relapsed colorectal cancer
35. NCI commences trial of Genta's bcl-2 antisense compound combined with chemotherapy for relapsed acute leukemia
36. NCI commences trial of Genta's Bcl-2 antisense compound combined with paclitaxel for relapsed small cell lung cancer
37. Programmed Cell Death Regulation: Basic Mechanisms and Therapeutic Opportunities. Lake Tahoe, NV, USA
38. Genta launches pivotal registration study of its lead antisense compound in malignant melanoma
39. Investigator reports major antitumor activity with Genta's antisense product G3139 in malignant melanoma-'Late breaking' session in American Assn for Cancer Research meeting in San Francisco includes major response and survival data of patients treated with G3139 and DTIC
40. Investigators at ASCO meeting report activity with Genta's antisense drug, Genasense (G3139), plus chemotherapy in women with advanced breast cancer
41. A phase I study of BCL-2 antisense G3139 (Genta) and weekly docetaxel in patients with advanced breast cancer and other solid tumors
42. A phase I trial of G3139, a BCL2 antisense drug, by continuous infusion (CI) as a single agent and with weekly taxol (T)
43. A phase I trial of an antisense oligonucleotide to bcl-2 (G-3139, Genta) and mitoxantrone in patients with metastatic hormone refractory prostate cancer
44. US Oncology announces opening of phase III trial of Bcl 2 antisense plus chemotherapy in melanoma
45. Genta's lead antisense drug genasense enhances activity of chemotherapy in mouse model of human breast cancer
46. BCL-2 antisense plus dacarbazine therapy for malignant melanoma
47. Genta announces orphan drug designation from food and drug administration and completes strategic review for its lead compound, Genasense
48. Genta's CEO presents updated clinical trials results and proposed new clinical trials at anticancer conference
49. Investigators report activity for Genasense(TM), Genta's lead antisense compound, in combination therapy for prostate cancer
50. Genta's lead antisense drug reported active in malignant melanoma; New data on antisense mechanism and clinical response reported in leading journal
51. A phase I, pharmacokinetic and biological correlative study of G319 (Bcl-2-antisense oligonucleotide) and docetaxel in patients with hormone-refractory prostate cancer (HRPC)
52. American Society of Hematology 42nd Annual Meeting - Overnight Report (Part II), San Francisco, CA, USA
53. Investigators report clinical activity of Genta's lead antisense drug in acute leukemia - New clinical findings presented at leading scientific meeting
54. Phase I trial of Genasense (G-3139, Genta Inc), a bcl-2 antisense (AS), in refractory (REF) or relapsed (REL) acute leukemia (AL)
55. Genta launches new clinical trials with Genasense in acute and chronic leukemia
56. Genta announces fourth quarter and year-end 2000 results and highlights
57. Genta launches phase III randomized trial with Genasense in multiple myeloma
58. Making sense of antisense
59. In vivo suppression of B cell lymphoma with bcl-2 antisense oligonucleotides